文献速递消化系统肿瘤

曲妥珠单抗耐药的HER2阳性晚期或复发性胃癌患者HER2状态再评估(KSCC1604)

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
PubMed 文献 · Eur J Cancer · 2018-11-02

本研究纳入33例一线曲妥珠单抗治疗后进展的HER2阳性晚期或复发性胃腺癌患者,再活检评估HER2状态。结果显示60.6%患者出现HER2丢失,免疫组化HER2 3+比例由治疗前72.7%降至治疗后39.4%。使用非10%中性缓冲福尔马林固定剂显著降低HER2阳性率。

要点

  • 曲妥珠单抗治疗后进展的HER2阳性胃癌患者中,60.6%出现HER2丢失。
  • 免疫组化HER2 3+比例由治疗前24例(72.7%)降至治疗后13例(39.4%)。
  • 使用非10%中性缓冲福尔马林固定剂显著降低HER2阳性率。

核心结论

  • 疾病进展后需再评估HER2状态以确定抗HER2靶向治疗的合适使用。
  • 结果强调福尔马林固定条件对HER2检测的重要性。

研究设计与样本

  • 本研究纳入一线曲妥珠单抗治疗后进展、且在完成曲妥珠单抗治疗后3个月内病理确诊为腺癌的晚期或复发性HER2阳性胃腺癌患者。
  • 收集对曲妥珠单抗耐药患者的再活检样本,重新评估HER2状态。
  • 在样本可得时对比分析EGFR扩增、c-met扩增及PIK3CA突变。

主要发现

  • 33例合格患者中,20例(60.6%)难治性疾病患者发现HER2丢失。
  • 免疫组化显示治疗后HER2过表达率大幅降低(治疗前HER2 3+:24例[72.7%] vs 治疗后HER2 3+:13例[39.4%])。
  • 使用非10%中性缓冲福尔马林固定剂显著降低HER2阳性率。
  • 曲妥珠单抗治疗前后EGFR扩增分别为10.3%和3.8%,c-met扩增分别为17.9%和4.2%,PIK3CA突变分别为4.0%和4.2%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-HER2 therapy has not demonstrated a survival advantage in the second-line setting of patients with HER2-positive gastric cancer. We conducted this study to assess changes in HER2 status and to identify possible biomarkers for acquired resistance after the use of trastuzumab as the first-line therapy. PATIENTS AND METHODS: Patients with advanced or recurrent HER2-positive gastric adenocarcinoma who were diagnosed with progressive disease after the first-line trastuzumab-based therapy and developed pathologically confirmed adenocarcinoma within 3 months after completion of trastuzumab-based therapy were enrolled in this study. We collected re-biopsied samples from the HER2-positive patients who had developed resistance to trastuzumab and re-evaluated their HER2 status. Amplification of EGFR and c-met, as well as PIK3CA mutation, were comparatively analysed when samples were available. RESULTS: Among 33 eligible patients, loss of HER2 was identified in 20 patients (60.6%) with refractory disease. Immunohistochemistry showed that the rate of HER2 overexpression was greatly reduced after therapy (pre-HER2 3+: 24 [72.7%] vs. post-HER2 3+: 13 [39.4%]). We found that the use of fixatives other than 10% neutral buffered formalin significantly reduced the HER2-positive rate. EGFR amplification, c-met amplification and PIK3CA mutation before and after trastuzumab-based therapy were observed in 10.3% and 3.8%, 17.9% and 4.2% and 4.0% and 4.2% of cases, respectively. CONCLUSION: Re-evaluation of HER2 status is needed to determine the appropriate use of anti-HER2-targeted therapy after disease progression. Our results also highlight the importance of formalin fixation conditions for HER2 testing.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018. PMID: 30391779. doi:10.1016/j.ejca.2018.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。